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ABSTRACT 
 
A key goal of our research is the targeted delivery of functional biopharmaceutical agents of interest, such as 
small interfering RNA (siRNA), to selected cells by means of receptor-mediated nanoparticle technologies. 
Recently, we described how pH-triggered, PEGylated siRNA-nanoparticles (pH triggered siRNA-ABC 
nanoparticles) were able to mediate the passive targeting of siRNA to liver cells in vivo. In addition, 
PEGylated siRNA nanoparticles enabled for long-term circulation (LTC siRNA-ABC nanoparticles, 
LEsiRNA nanoparticles) were shown to do the same to tumour cells in vivo. Further gains in the efficiency 
of siRNA delivery are expected to require active targeting with nanoparticles targeted for delivery and 
cellular uptake by means of attached biological ligands. Here we report on the development of a new 
synthetic chemistry and a bioconjugation methodology that allows for the controlled formulation of 
PEGylated nanoparticles which surface-present integrin-targeting peptides unambiguously and so enable 
integrin receptor-mediated cellular uptake. Furthermore, we present delivery data that provide a clear 
preliminary demonstration of physical principles that we propose should underpin successful, bonefide 
receptor-mediated targeted delivery of therapeutic and/or imaging agents to cells. 
 
KEYWORDS: Integrin ligand, integrin receptor, nanoparticles, delivery, cellular uptake, siRNA, RNAi 
 
 
 
INTRODUCTION 
 
The specific targeting of nanoparticles to target cells in an 
organ of interest has been a long-term goal of many 
laboratories interested in using nanoparticles to mediate 
the functional delivery of biopharmaceutical agents 
(including nucleic acids) to defined target cells. One of the 
main problems in using targeting ligands in conjunction 
with nanoparticles is the competition between specific-
binding mediated cell entry and non-specific enhanced cell 
uptake mechanisms (Andreu et al, 2008). Previously, we 
have observed that non-specific effects can be completely 
overwhelming (Waterhouse et al, 2005), an observation 
that has led to a series of further studies (Wang et al, 2009) 
intended to determine and characterize those factors that 
might influence non-specific enhanced cell uptake 
mechanisms such as nanoparticle size and heterogeneity, 
surface hydrophilicity and charge, not to forget other 
factors such as ligand conformation, points of attachment 
and surface density. 450 
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Recently, we described how pH-triggered, PEGylated 
siRNA nanoparticles (also known as pH-triggered 
siRNA-ABC  nanoparticles according to our recently 
described  ABCD nanoparticle structural paradigm 
(Kostarelos and Miller, 2005; Thanou et al, 2007; Miller, 
2008a; Miller, 2008b). These nanoparticles with a 
surface-covering of 5mol% polyethylene glycol 2000 
(PEG
2000) were able to mediate the passive targeting of 
siRNA to liver cells in vivo, thereby providing proof of 
concept for an effective RNAi therapeutic approach to 
the treatment of hepatitis B virus infections 
(siFECTplus
TM nanoparticles) (Carmona et al, 2009). In 
addition, PEGylated siRNA nanoparticles enabled for 
long-term circulation (LTC siRNA-ABC nanoparticles; 
LEsiRNA nanoparticles) were shown to do the same to 
tumour cells in vivo, thereby providing proof of concept 
for an effective RNAi therapeutic approach to cancer 
treatment (Kenny et al, 2011). In the case of the pH-
triggered, PEGylated siRNA nanoparticles, the PEG 
coating required for the biological stabilization of these 
nanoparticles was introduced by a purpose-designed 
post-coupling methodology. 
 
Here, we report how this methodology has now been 
adapted to introduce integrin-targeting peptide motifs 
onto liposome and nanoparticle surfaces and so enable 
integrin receptor-mediated cellular uptake of agents to 
cells. There have been some spectacular data obtained in 
recent years using αvβ6 integrin-receptor binding motifs 
for receptor-mediated delivery of different imaging 
agents to cells in vivo ( DiCara et al, 2007; Hausner et al, 
2007; DiCara et al, 2008; Hausner et al, 2009). We have 
described previously the use of integrin-receptor 
targeting peptides to promote functional gene delivery to 
cells (Harbottle et al, 1998; Cooper et al, 1999). Here, we 
now report on the use of an alternative cyclic 
pentapeptide construct that makes use of a single D-
tyrosyl amino acid residue to present the arginine-
glycine-aspartate (RGD) amino acid residue triad in an 
“active” conformation capable of mediating intracellular 
delivery through αvβ3/5  receptor binding and 
internalization (Chen et al, 2004). Arginine-glycine-
glutamate (RGE) controls are also reported in order to 
provide the means to demonstrate pure integrin-receptor 
mediated cellular uptake by RGD presenting imaging 
nanoparticles. 
 
MATERIALS AND METHODS 
 
Lipids and synthetic chemistry 
Dioleoyl L-α-phosphatidylethanolamine (DOPE) 1, 
dimyristoyl L-α-phosphatidylcholine (DMPC) 2 (Sigma), 
DOPE-Lissamine-Rhodamine B (DOPE-Rhoda) 3 were 
obtained from Avanti Polar Lipids (USA) (Figure 1). 
General synthetic procedures were performed as described 
previously (Carmona et al, 2009; Mével et al, 2010). 
Syntheses of N
1-cholesteryloxycarbonyl-3,7-diazanonane-
1,9-diamine (CDAN) 4 and cholesteryl-aminoxy (CA) 
lipid 5 were performed as described previously (Keller et 
al, 2003; Oliver et al, 2004; Carmona et al, 2009) (Figure 
1). The synthesis of other compounds necessary for our 
experiments were performed as described (Scheme 1). 
HPLC purification of final products required the use of 
Vydac C-4 reversed phase preparative column with 
1ml/min flow rate: Mobile phases as follows used 
trifluoroacetic acid (TFA); A: H2O (0.1%, v/v, TFA); B: 
MeCN (0.1%, v/v, TFA); C: MeOH (0.1%, v/v, TFA). 
Program set at: 0-15.0min (100%, A), 15.1-25.0min (0- 
100%, B), 25.1-45min (100%, C), 45.1-55min (100%, A). 
Elution parameters: RGD-PEG
1000-CHO 13a R t 15.2min, 
RGE-PEG
1000-CHO  13b R t 14.8min, PrNHCO-PEG
1000-
CHO  14 R t 15.8min, CA lipid 5 R t 23.8min, RGD-
PEG
1000-CA  15a product Rt 24.1min, RGE-PEG
1000-CA 
15b  product Rt 23.8min, and PrNHCO-PEG
1000-CA  16 
product Rt 26.3min; mass spectrometry: m/z (ESI) 1878 
(M-H
-, RGD-PEG
1000-CHO  13a), 1917 (MNa
+, RGE-
PEG
1000-CHO 13b), 1326 (MH
+, PrNHCO-PEG
1000-CHO 
14), 2406 (MH
+, RGD-PEG
1000-CA  15a), 2443 (MNa
+, 
RGE-PEG
1000-CA 15b), 1869 (MNa
+, PrNHCO-PEG
1000-
CA 16) (Figure 1). 
 
Liposome and nanoparticle formulations 
CL1 and CL2 were prepared in the following way (Table 
1). Designated lipids were dissolved in chloroform at 
5mg/ml and then appropriate aliquots were combined in a 
presilanized round-bottom flask (5ml). In each case, the 
organic solvent was evaporated to dryness to form an even 
thin lipid film that was further purged with a stream of 
argon gas to remove residual traces of the organic solvent. 
The lipid film was hydrated using double distilled H2O 
(ddH2O) to give a multilamellar liposome suspension that 
was subsequently subjected to sonication in a water bath at 
40ºC for 30min (sonomatic® water bath, Langford 
Ultrasonics, 33 kHz ultrasound frequency). Post-
sonication, small unilamellar vesicles (50-80nm) (B-
component, CL1 or CL2) were diluted to 1.5mg/ml and 
incubated at room temperature for 15min. Thereafter, 
appropriate aliquots of α-terminally modified-PEG
1000-
CHO 13a, 13b or 14 (1mg/ml in water, CD molecules) 
were introduced for post-coupling such that their final 
composition was between 1 and 10mol% of total lipid. The 
pH of solution was monitored by pH boy (Camlab Ltd, 
Cambridgeshire, UK) and adjusted to pH 4 if required by 
addition of small aliquots of aqueous solutions of NaOH 
(0.99M) or HCl (0.99M). On completion of the reaction 
(approximately 16-24hr) (as judged by HPLC analysis), 
the solution pH was accurately readjusted to pH 7 
resulting in 10mol% PEGylated BCD1  and 1-5mol% 
PEGylated BCD2 nanoparticles, respectively, ready for 
use. 1-5mol% PEGylated ABCD2 nanoparticles were 
prepared by combining 1-5mol% PEGylated BCD2 
nanoparticles with various volumes of aqueous 4mM 
HEPES, pH 7.0-7.4, siRNA solution (50µM A-
component) under heavy vortex conditions (final [siRNA] 
typically 100μg/ml; 7μM) using a lipid:siRNA ratio of 
12:1 (w/w) that correlates with a lipid-nucleic acid N/P 
charge ratio of approximately 2. 
 
FACS analysis 
These experiments were performed on a FACS Calibur 
instrument (BD Biosciences). In each set of indicated 
experiments 1, 2 or 5mol% PEGylated ABCD2  nano-
particles (140±60nm) were prepared with siRNA 
([siRNA] 80pmoles/well) and uptake studies performed 
with HUVEC cells previously grown to 80% confluent at 
37
oC, 10% CO2. 451 
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Figure 1. Main lipids used and oxime lipid conjugates formed during the reported investigations. Main lipids were used to prepare 
liposomes CL1 and CL2 and hence 10mol% PEGylated BCD1 and 1-5mol% PEGylated BCD2 nanoparticles.  
 
 
 
 
Scheme 1. Syntheses of α-terminally modified-PEG
1000-CHOs: i) a) Side chain protected, Fluorenylmethyloxycarbonyl (Fmoc) 
amino acid residue N-terminal coupling of L-Arg(NPbf), L-Lys(εBoc), D-Tyr(OtBu) and finally L-Asp(OtBu) [or L-Glu(OtBu)] to 
glycyl-2-chlorotrityl resin 6 using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) with di-
isopropylethylamine (DIPEA) to mediate residue coupling and 2% (v/v) each of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 
piperidine in dimethylformamide (DMF) for Fmoc deprotection between rounds of peptide bond formation: b) resin release with 20% 452 
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(v/v) each of acetic acid and trifluoroethanol (TFE) in CH2Cl2, 31-78%; ii) a) 3eqv diphenylphosphoryl azide (DPPA) in dry DMF, 5 
eqv NaHCO3, 0
oC – ambient temperature, pH 8.5, 74-80%:  b) 2.5% (v/v) each H2O and triisopropylsilane (TIS) in trifluoroacetic 
acid (TFA), 80-100%; iii) a) HO-C2H4-OH, Al2O3, CCl4, reflux, 27%: b) pentafluorophenol (PfpOH), N,N'-Dicyclohexylcarbo-
diimide (DCC), EtOAc, 71%; iv)  a) amino-PEG
1000-propionic acid, 4 eqv triethylamine (TEA), CHCl3, reflux, 84%: b) 1.2 eqv 
PfpOH, 1.2 eqv DCC, EtOAc, 76%;  v) 0.2M Na2HPO4, 0.1M NaOH, 69-100%; vi) 10% (v/v) TFA in H2O, 100%; vii)  a) 
propylamine (PrNH2), 4 eqv TEA, CHCl3, reflux, 100%: b) 10% (v/v) TFA in H2O, 51% (v/v). 
 
 
 
Table 1. Lipid compositions of two liposome formulations prepared in double distilled water with final diameters of 50-80nm. For 
lipid structures see Figure 1. 
 
Molar % of Lipid  CL1  CL2 
DOPE 1 -  60 
DMPC 2 59  - 
DOPE-Rhoda 3 1  1 
CDAN 4 -  20 
CA 5 20 10 
Chol 17 20  9 
 
 
 
 
RESULTS 
 
Post-coupling represents an optimal way to attach a 
biological targeting ligand of interest to a nanoparticle 
surface with controlled mol% attachment and ligand 
orientation (Scheme 2). Our approach to the development 
of a post-coupling methodology has been to learn from the 
chemistry employed to create pH-triggered, PEGylated 
siRNA nanoparticles (as mentioned in the Introduction) in 
order to design-hybrid targeting ligands (L) that comprise 
a peptide targeting moiety conjugated to a PEG
1000 
extension chain enabled for postcoupling to a nanoparticle 
surface (Scheme 2). RGD peptides and corresponding 
RGE control peptides were prepared as follows (Scheme 
1). Starting with glycyl-2-chlorotrityl solid-phase peptide 
resin  6, the desired pentapeptide RGD-targeting moiety 
was prepared in an open chain, protected form 7 by solid-
peptide synthesis, then subject to cyclization and 
deprotection to give cyclic pentapeptide 8a. A control 
cyclic-RGE pentapeptide 8b (with aspartate [D] replaced 
by glutamate [E]) was prepared in an equivalent manner. 
Thereafter, the aldehyde functionality of 4-
carboxybenzaldehyde  9 was acetal protected and the 
carboxy function was activated for coupling by means of 
pentafluorophenol (PfpOH) esterification giving 10. 
Reagent 10 was then coupled to amino-PEG
1000-propionic 
acid and the free carboxylate activated once again for 
coupling by means of PfpOH esterification giving 
heterofunctional PEG
1000 moiety 11. The coupling of 11 to 
8a or 8b resulted in RGD acetal 12a and RGE acetal 12b 
respectively. Routine acetal deprotection yielded the 
desired products RGD-PEG
1000-CHO  13a and control 
RGE-PEG
1000-CHO  13b  (Scheme 1). An alternative 
control aldehyde was obtained through combination of 
heterofunctional PEG
1000 moiety 11 with propylamine 
followed by acetal deprotection resulting in the non-
peptide control product PrNHCO-PEG
1000-CHO  14 
(Scheme 1). All three α-terminally modified-PEG
1000-
CHO compounds prepared as described above were used 
in subsequent experiments described below. 
 
Using all three α-terminally modified-PEG
1000-CHO 
compounds in turn, coupling reactions were performed 
individually with neutral cholesteryl-aminoxy lipid (CA) 5 
(Figure 1) and then with neutral liposomes (equivalent in 
composition to CL1, Table 1). Reactions were monitored 
by HPLC and mass spectrometry in water at pH4 and 
shown to reach completion after 16-24h stirring at ambient 
temperature giving 15a,  15b, or 16 as appropriate. 
Liposome-coupling experiments were then performed 
under similar conditions in order to couple RGD-PEG
1000-
CHO 13a (or control aldehydes RGE-PEG
1000-CHO 13b 
and PrNHCO-PEG
1000-CHO  14) to alternative liposome 
formulations CL1 or CL2 (Table 1, Figure 1), making use 
of CA lipid 5 once again in order to present the aminoxy 
functional groups required for conjugation of liposome 
surfaces with each α-terminally modified-PEG
1000-CHO 
compound in turn (Scheme 2). Upon conclusion of these 
liposome-coupling reactions, pH was raised to 7 in order 
to stabilize the resulting oxime bonds and the resulting 
PEGylated liposomes.  Resulting ligand-PEGylated 
liposomes (approx 100nm in diameter) were described as 
belonging to either BCD1 or BCD2 nanoparticle families 
depending upon whether the parent liposome formulation 
used in preparation was CL1 or CL2, respectively. 
 
Initially BCD1 family members RGD-BCD1, RGE-BCD1 
and PrNHCO-BCD1 were prepared with 1mol% of DOPE- 453 
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Scheme 2. Schematic illustration of nanoparticle formulations involving the inclusion of an aminoxy coupling lipid by a formulation 
procedure known as premodification followed by the post coupling of α-terminally ligand (L)-modified PEG aldehydes (L-PEG-
CHO). 
 
 
Rhoda 3 for fluorescence microscopy cell uptake studies. 
The results demonstrate that only 10mol% PEGylated 
RGD-BCD1 nanoparticles were capable of delivering 
measurable and observable levels of fluorescent-label to 
integrin-rich human umbilical vein endothelial cells 
(HUVEC) (Figure 2A). These data are completely 
consistent with receptor specific-binding mediated cell 
entry. The discrimination between RGD presenting and 
control nanoparticles is near total. This is very interesting 
in view of the physical properties of BCD1 nanoparticles, 
namely approx 100nm in diameter, 10mol% PEGylation 
with PEG
1000, and a ζ-potential of essentially zero mV. 
The lack of charge originates from the fact that the 
majority lipid components needed to prepare CL1 
liposomes were neutral while the minority CA lipid 5 
component possesses an aminoxy functional group 
unprotonated at pH 7 due to its pKa value of about 4.5 
(compared with the pKa values of more typical amine 
functional groups that are found around 10) (Castro, 
1990). We would argue that such nanoparticle physical 
properties could be an ideal starting point from which to 
optimize receptor specific cellular uptake of nanoparticles 
relative to non-specific enhanced cell uptake. 
 
Subsequently,  BCD2 family members RGD-BCD2, RGE-
BCD2 and PrNHCO-BCD2 were prepared with 1.0 mol% of 
DOPE-Rhoda  3 and up to 5mol% of each α-terminally 
modified-PEG
1000-CHO for fluorescence-activated cell 
sorting (FACS) studies. In addition these cationic liposome 
systems were further combined with a non-functional nucleic 
acid (small interfering RNA [siRNA]) (A component) in 
order to neutralize the positive charge and convert the BCD2 
family members in to a varieties of corresponding low 
charge ABCD2 nanoparticles with lipid:siRNA N/P charge 
ratios of approximately 2. The physical properties of these 
nanoparticles were diameters of approximately 140nm, up to 
5mol% PEGylation with PEG
1000, and a ζ-potential of less 
than 10mV. In these cases, FACS studies were performed 
with low charge 1-, 2- and 5mol% PEGylated RGD-
ABCD2, RGE-ABCD2 and PrNHCO-ABCD2 
nanoparticles. In each case, the discrimination between RGD 
presenting and control nanoparticles was still clearly present 
and was found to increase as a function of the mol% 
PEGylation coverage with PEG
1000 (Figure 2B). The fact that 
the discrimination was not as substantial as observed above 
(Figure 2A) appears to be due to the lower mol% levels of 
PEGylation coverage and the presence of residual 
nanoparticle charge. Therefore, control of both PEGylation 
levels (plus other PEG-structure related criteria) and residual 
charges are essential in order to optimize receptor mediated 
cell uptake in preference to non-specific enhanced cell 
uptake mechanisms. 
 
DISCUSSION 
 
Biological receptor mediated functional delivery of imaging 
agents is well established (DiCara et al, 2007; DiCara et al, 
2008; Hausner et al. 2007; Hausner et al, 2009), even of 
genes (Harbottle et al, 1998; Cooper et al, 1999). However, 
receptor-mediated delivery cannot be taken as a given 
following the covalent attachment of a biological targeting 
ligand to a nanoparticle (Waterhouse et al, 2005; Andreu et 
al, 2008). Therefore, in our view, receptor-mediated delivery 
phenomena should never be treated with the casual 
assumption that receptor-mediation is inevitable once an 
appropriate receptor-specific ligand has been mounted on a 
nanoparticle surface. Any given receptor-specific ligand 
should in fact be subject to a standard set of trial experiments 454 
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to ensure that the biophysical properties of a nanoparticle 
platform and the presentation of the receptor-specific ligand 
are optimized for bonefide receptor-mediated delivery of the 
corresponding nanoparticle. In this paper we describe just 
such a set of trial experiments (Figure 2) with sufficient 
controls to demonstrate clearly that specific receptor-
mediated uptake by cells has been enabled over background. 
Accordingly, we would like to propose that both studies 
involving first the delivery of an imaging agent and then 
second a potential agent of pharmaceutical interest (API), 
should be standard assays to perform and demonstrate before 
all else that a nanoparticle-attached ligand is truly a receptor-
specific ligand in the context of the nanoparticle platform to 
which the ligand is covalently attached. If this is not shown, 
then nanoparticle biophysical properties, ligand attachment 
and orientation, and mol% ligand presentation should all be 
systematically altered until specific receptor-mediated cell 
uptake can be observed substantially over and above any 
non-specific enhanced cell uptake background (Kamaly et al, 
2009; Kamaly et al, 2010). 
 
A: 
RGD‐BCD1 imaging nanoparticles RGE‐BCD1 imaging nanoparticles
 
 
B: 
 
 
Figure 2. A.  Fluorescence microscopy of HUVEC cells, 
previously grown to 80% confluent at 37
oC with 10% (v/v) CO2, 
treated with 10mol% PEGylated BCD1 nanoparticles prepared 
from RGD-PEG
1000-CHO 13a or RGE-PEG
1000-CHO 13b. Cells 
were in contact with nanoparticles for at least 4hr prior to 
mounting and observation of rhodamine fluorescence under a 
NiKon 600 Fluorescence microscope. B. Fluorescence activated 
cell-sorting (FACS) analysis involving HUVEC cells. Cell 
uptake was determined after 4hr using rhodamine fluorescence 
and detected using the FL-2 channel. Data were plotted as a 
function of theoretical maximum of cell uptake. Data shown 
come from an experiment with 5mol% PEGylated ABCD2 
nanoparticles. Other similar experiments were conducted with 1 
and 2mol% PEGylated ABCD2 nanoparticles. AB corresponds 
with simple siRNA-lipoplex control nanoparticles, formulated 
from CL2 cationic liposomes and an equivalent final [siRNA]. 
 
 
In our case here, we can say with confidence that our post-
coupling chemistry and methodology for the attachment of 
integrin-targeting RGD ligands has resulted in the 
successful formation of integrin-targeted imaging 
nanoparticles that can also mediate integrin-specific 
delivery of an API such as siRNA to αvβ3/5  integrin-
receptor presenting cells. Therefore, this post-coupling 
chemistry and premodification-postcoupling methodology 
could be applicable to other nanoparticle platforms with 
equal success provided that the biophysical properties of 
the nanoparticle platform also conform to the following 
biophysical parameters: 
 
• Nanoparticle dimensions of approx 100nm in diameter  
• Nanoparticle ζ-potential values that converge on neutral (0 
mV) 
• Nanoparticle ligand surface coverage of approx 2 mol% (or 
higher) 
 
Further research with this and other nanoparticle systems 
will now be needed to demonstrate if these three 
nanoparticle “rules” for receptor-mediated cell entry are 
indeed general rules or simply guidelines for receptor-
mediated cellular uptake of nanoparticle systems by 
corresponding receptor expressing cells in vitro, ex vivo 
and/or in vivo. 
 
CONCLUSIONS 
 
The data described here represent the completion of a first 
study involving the preparation of ligand-mounted 
PEGylated nanoparticles constructed by a bespoke pre-
modification postcoupling methodology. Data suggest for 
the first time in our hands that this methodology may be 
used to ensure that receptor mediated cell uptake of 
attached nanoparticles can be “engineered” to dominate 
non-specific enhanced cell uptake mechanisms. 
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PEG; polyethylene glycol 
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1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-
diamine 
CA; cholesteryl-aminoxy lipid 
DOPE; dioleoyl L-α-phosphatidylethanolamine  455 
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DMPC; dimyristoyl L-α-phosphatidylcholine 
DOPE-Rhoda; Lissamine-rhodamine B-DOPE 
HBTU; 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluro-
nium hexafluorophosphate 
DIPEA; di-isopropylethylamine  
DBU; 1,8-diazabicyclo[5.4.0]undec-7-ene 
DMF; dimethylformamide 
TFE; trifluoroethanol 
DPPA; diphenylphosphoryl azide  
TIS; triisopropylsilane  
TFA; trifluoroacetic acid 
PfpOH; pentafluorophenol  
DCC; N,N'-Dicyclohexylcarbodiimide 
TEA; triethylamine 
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